Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Synonyms
apixabanum
apixabán
Apixaban
Brand Names
Mint-apixaban
Nra-apixaban
ELIQUIS 30-Day Starter Pack
Auro-apixaban
Teva-apixaban
Apo-apixaban
Taro-apixaban
Sandoz Apixaban Tablet
Ag-apixaban
Jamp Apixaban
Ach-apixaban
Apixaban
Apixaban Accord
Pro-apixaban
Nat-apixaban
Mar-apixaban
Riva Apixaban
Sandoz Apixaban Sdz
Bio-apixaban
M-apixaban
Eliquis
Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682